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A B S T R A C T   
Influenza viruses are responsible for several pandemics and seasonal epidemics and pose a major public health 
threat. Even after a major outbreak, the emergence of drug-resistant influenza viruses can pose disease control 
problems. Here we report a novel 6E3 monoclonal antibody capable of recognizing and binding to the H275Y 
neuraminidase (NA) mutation, which has been associated with reduced susceptibility of influenza viruses to NA 
inhibitors. The 6E3 antibody had a KD of 72.74 μM for wild-type NA and 32.76 pM for H275Y NA, suggesting that 
it can identify drug-resistant pandemic H1N1 (pH1N1) influenza virus. Molecular modeling studies also suggest 
the high-affinity binding of this antibody to pH1N1 H275Y NA. This antibody was also subject to dot-blot, 
enzyme-linked immunosorbent assay, bare-eye detection, and lateral flow assay to demonstrate its specificity 
to drug-resistant pH1N1. Furthermore, it was immobilized on Au nanoplate and nanoparticles, enabling surface- 
enhanced Raman scattering (SERS)-based detection of the H275Y mutant pH1N1. Using 6E3 antibody-mediated 
SERS immunoassay, the drug-resistant influenza virus can be detected at a low concentration of 102 plaque- 
forming units/mL. We also detected pH1N1 in human nasopharyngeal aspirate samples, suggesting that the 
6E3-mediated SERS assay has the potential for diagnostic application. We anticipate that this newly developed 
antibody and SERS-based immunoassay will contribute to the diagnosis of drug-resistant influenza viruses and 
improve treatment strategies for influenza patients.   
1. Introduction 
Pandemics due to viruses are great threats to public health and incur 
catastrophic effects on the global economy (A. H. Reid et al., 2004; 
Bedford et al., 2015; Petrova and Russell, 2018; Taubenberger et al., 
2019). The United Nations has reported that the current pandemic 
caused by the severe acute respiratory syndrome coronavirus 2 (SAR-
S-CoV-2) is a global health crisis due to its impact on both health and the 
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economy (Sharma et al., 2020). Before the SARS-CoV-2 outbreak, the 
last pandemic was caused by the influenza H1N1 (pH1N1) virus in 2009 
(Medina and García-Sastre, 2011). Approximately 60.8 million cases, 
274,304 hospitalizations, and 12,468 deaths were reported in the United 
States from April 12, 2009, to April 10, 2010, due to pH1N1(Medina and 
García-Sastre, 2011; Vijaykrishna et al., 2010). Fortunately, pH1N1 is 
susceptible to the neuraminidase (NA) inhibitors such as oseltamivir, 
peramivir, and zanamivir, allowing the treatment of influenza 
virus-infected patients (Hayden et al., 1997; Moscona, 2005; Shetty and 
Peek, 2012). However, pH1N1 has become one of the causative agents 
for seasonal influenza, thus remaining a threat to human health. 
Furthermore, influenza virus isolates that have acquired resistance to 
NA inhibitors have been reported (Hayden and de Jong, 2011; 
McKimm-Breschkin, 2013). Therefore, influenza viruses, particularly 
drug-resistant pH1N1, are poised for re-emergence and may cause large 
outbreaks in the future. A crucial step in controlling the outbreak of 
infectious disease is the rapid and accurate detection of virus strains. 
Since oseltamivir is the most widely used anti-influenza medication 
(Moscona, 2005), the re-emergence of oseltamivir-resistant influenza 
viruses pose a serious threat to human health (Hayden and de Jong, 
2011). Oseltamivir resistance of the pH1N1 strain has been reported to 
be almost always associated with the H275Y mutation, an amino acid 
substitution from histidine to tyrosine at position 275 of NA (Brookes 
et al., 2011; Ginting et al., 2012). Since the H275Y mutation is located at 
the NA active site, the mutation causes damage to the NA structure and 
consequently interferes with the rearrangement essential for effective 
oseltamivir binding (Brookes et al., 2011; Tolentino-Lopez et al., 2013). 
Several studies suggest that the pH1N1 virus carrying the H275Y mu-
tation is gradually becoming dominant, resulting in an increasing 
number of pH1N1 cases where a prescription for oseltamivir is ineffec-
tive (Hurt, 2014; Jones et al., 2019; Meijer et al., 2009). Therefore, it is 
important to accurately distinguish the H275Y mutant pH1N1 virus 
from the wild-type (WT) pH1N1. 
Influenza virus-infected patients are mainly diagnosed using rapid 
influenza diagnostic tests (RIDTs), which are immunoassays that can 
identify the presence of influenza nucleoprotein antigens in respiratory 
specimens (Green, 2018; Trombetta et al., 2018). Although the methods 
are rapid, simple, and cost-effective, no commercially available RIDT 
can distinguish antiviral drug-resistant influenza viruses (Green, 2018). 
Molecular diagnostic methods can provide information about the anti-
viral resistance of influenza viruses; however, they are time-consuming, 
labor-intensive, expensive, and require highly trained personnel and 
validation of reagents (Jang et al., 2020). The development of immu-
noassays for drug-resistant influenza viruses will help accurately di-
agnose drug resistance in patients infected with the influenza virus to 
guide treatment and prevent further spread of mutant viruses. 
Here we report a newly developed 6E3 antibody that specifically 
recognizes the oseltamivir-resistant influenza virus that carries the 
H275Y NA mutation. The binding affinity of the 6E3 antibody was 
verified by enzyme-linked immunosorbent assay (ELISA) and docking 
simulations. Then, the antibody was applied to different diagnostic 
formats such as the dot-blot, bare-eye detection using Au nanoparticles 
(NPs), and lateral flow assay to evaluate its applicability for detecting 
the H275Y mutant NA. Furthermore, to increase the sensitivity of the 
system, we immobilized the antibody onto an atomically flat Au nano-
plate and Au NPs, acting as an immune substrate and immunoprobe, 
respectively, and performed surface-enhanced Raman scattering (SERS)- 
based immunoassay for oseltamivir-resistant pH1N1. SERS is a well- 
known phenomenon that increases the Raman signals of molecules 
adjacent to metallic nanostructures (Sharma et al., 2012). SERS-based 
immunoassay is considered a promising method for viral detection 
because of its single-molecule sensitivity, molecular fingerprint spec-
trum, and photostability (Eom et al., 2019a,b; Lee et al., 2018; Sharma 
et al., 2012). The 6E3 antibody-mediated SERS immunoassay enables us 
to detect the H275Y mutant influenza virus sensitively and selectively. 
Moreover, the 6E3-mediated SERS assay allows the diagnosis of the 
mutant virus in human nasopharyngeal aspirate samples. Our findings 
suggest that SERS-based immunoassay using the 6E3 antibody could 
help diagnose drug-resistant pH1N1 infections and help clinical practi-
tioners to develop an effective treatment for influenza virus infection. 
2. Materials and methods 
2.1. Materials 
All chemicals were purchased from Sigma-Aldrich (MO, USA) unless 
otherwise specified. Absorbent pads (CFSP203000, cellulose fiber) and 
NC membrane (HF090MC100) were purchased from Millipore (MA, 
USA). The polyester conjugate pad was purchased from Boreda Biotech 
(Seongnam, South Korea). The anti-influenza A virus nucleoprotein 
antibody (ab20343) was purchased from Abcam (Cambridge, UK). WT 
and H275Y NA proteins were purchased from Sino Biological (Beijing, 
China). DENV1-EP, HG-NS1-3-6H, CHIKV-EP2, and JEV-E domain III 
were provided by the BioNano Health Guard Research Center of South 
Korea. Cys3-protein G was purchased from Bioprogen (Daejeon, Korea). 
Malachite green isothiocyanate (MGITC) was purchased from Setareh 
Biotech (OR, USA). pH1N1 (A/California/07/2009) and H275Y pH1N1 
mutant virus (H275Y mutation; A/Korea 2785/2009 pdm: NCCP 42017) 
were obtained from the National Culture Collection for Pathogens 
(NCCP) operated by the Korea National Institute of Health (KNH). RSV 
was obtained from ATCC. The I223 R/H275Y and I223R pH1N1 mutant 
virus was prepared as previously described (Guk et al., 2020). I223R 
mutation was introduced within the NA fragment by the forward primer: 
5′ AGTTGGAGAAACAATCGTTTGAGAACACAA and reverse primer: 5′
TTGTGTTCTCAAACGATTGTTTCTCCAACT. The titers of viruses were 
determined using a one-step real-time polymerase chain reaction 
(RT-PCR) kit (Promega, WI, USA) following the manufacturer’s 
instructions. 
2.2. Production of 6E3 antibody 
The 6E3 antibody screening procedures are similar to the previous 
report (Guk et al., 2020). A large naïve human Fab phage display library 
(3 × 1010) from the Korea Research Institute of Bioscience and 
Biotechnology (KRIBB) was used (Guk et al., 2020; Kim et al., 2017). 
Briefly, immunotubes (Nunc, MA, USA) were coated with 100 μg WT NA 
or H275Y NA overnight at 4 ◦C, washed twice with phosphate-buffered 
saline (PBS), and blocked with skim milk in PBS (4%) for 1 h at 37 ◦C. 
The antibody library phages were preincubated with WT NA for 2 h at 
37 ◦C. The subtracted phages were then incubated with H275Y NA for 1 
h at 37 ◦C. After washing with 0.05% Tween 20 in PBS (PBST), bound 
phages were eluted with glycine-HCl (0.1 M, pH 2.2) and neutralized 
with Tris base (2 M). The eluted phages were amplified by infecting 
Escherichia coli TG1 cells, followed by superinfection with helper phages 
(VCSM13) (Marks et al., 1991). The amplified phages were then subject 
to another round of panning; three rounds of panning were conducted. 
After the third round of panning, 500 colonies were randomly 
selected from the output plate to screen individual clones for specific 
binding to H275Y NA. The colonies were cultured in Super Broth me-
dium containing ampicillin (100 μg/mL) until an optical density of 0.5 
was reached. Fab expression in E. coli TG1 cells was induced overnight at 
30 ◦C by adding isopropyl β-D-1-thiogalactopyranoside to a final con-
centration of 1 mM. The culture supernatant of each clone was subjected 
to ELISA. In detail, a microtiter plate was coated with 100 ng/well of 
H275Y NA in sodium carbonate buffer (50 mM, pH 9.6) and incubated at 
4 ◦C overnight. After blocking with 2% BSA in PBS, goat F (ab’)2 anti- 
human IgG (Fab’)2-horseradish peroxidase (HRP) antibody (ab98533, 
Abcam) was used for colorimetric detection of bound clones using the 
3,3′,5,5′-tetramethylbenzimidine (TMB) substrate (BD Biosciences, CA, 
USA). Clones showing positive signals in ELISA were subjected to DNA 
sequencing, and the nucleotide sequences of the variable heavy chain 
(VH) and variable kappa light chain (VK) regions were determined. 
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To convert the selected Fabs into the whole IgG format, the VH and 
VK sequences were amplified by PCR and combined with the leader 
sequences of IgG heavy and light chains, respectively, by overlap 
extension PCR using Pfu DNA Polymerase (Thermo Fisher Scientific, 
MA, USA). The VH and VK with leader sequences were sequentially 
cloned into the EcoRI-ApaI and HindIII-BsiWI sites, respectively, in the 
antibody expression cassette (pdCMVdhfrC) containing the human 
constant region of γ1 heavy chain (Cγ1) and Cκ gene (Yoon et al., 2006). 
For transient IgG expression, the resulting expression plasmid was 
introduced into HEK293T cells using Lipofectamine (Invitrogen, CA, 
USA) according to the manufacturer’s instructions, and the transfected 
cells were cultured in protein-free medium (CD293, Invitrogen). IgG was 
purified from the culture supernatant by affinity chromatography on a 
protein A-agarose column (Millipore), and its expression and purity 
were analyzed by western blotting and SDS-PAGE, respectively. 
2.3. ELISA 
Microtiter wells were coated with the purified WT NA or H275Y NA 
(100 ng/well) in 50 mM sodium carbonate buffer (pH 9.6) at 4 ◦C 
overnight, blocked with BSA (2%) in PBS, and washed with PBST. A 
purified 6E3 antibody was then added to each well pre-coated with 100 
ng NA. HRP-conjugated goat anti-human IgG was used for the detection 
of bound antibody. Color was developed using the TMB substrate re-
agent set, and the absorbance at 450 nm was measured using a micro-
titer plate reader (Emax; Molecular Devices, CA, USA). Affinity was 
determined as the antigen concentration required to inhibit 50% of 
binding activity, and the binding affinity (KD) value was calculated from 
a Klotz plot. Proteins (100 ng/well; BSA, DENV1-EP, HG-NS1-3-6H, 
CHIKV-EP2, and JEV-E domain III) and viruses (106 PFU/mL; WT 
pH1N1, H275Y pH1N1, I223R pH1N1, I223 R/H275Y pH1N1, and RSV) 
were tested using the same procedures. 
2.4. Homology modeling of 6E3 antibody 
The 3D structure of the 6E3 antibody was constructed by homology 
modeling using the latest version of the MODELLER program (Šali and 
Blundell, 1993). As the structural template for the 6E3 antibody, we 
used the X-ray crystal structure of the Fab fragment of a phage-derived 
antibody (PDB entry: 2QQN) that specifically blocks the binding of 
vascular endothelial growth factor (VEGF) to neuropilins (Yu et al., 
2012). A high-quality structure was expected in homology modeling 
because the amino-acid sequences of the 6E3 and the template were 88% 
identical. The conjugate gradient method and molecular dynamics 
simulations were applied during the entire course of homology modeling 
to find the optimal 6E3 structures by minimizing the violation of spatial 
restraints. The atomic coordinates of the gap regions were calculated 
from a randomized distorted structure to link the two anchoring atoms, 
as implemented in the original MODELLER program. The loop regions 
were modeled with the enumeration algorithm to cope with the struc-
tural flexibility (Fiser et al., 2000). Lastly, the calculated structure with 
the lowest MODELLER objective function was selected as the all-atom 
model for the 6E3 antibody. 
The homology-modeled structure of the 6E3 antibody served as the 
receptor model to address the differential binding modes between the 
WT and H275Y mutant NAs. Two pentapeptide fragments comprising 
residues at the 273–277 position of NA were selected as the simplified 
models for the WT and H275Y mutant under the assumption that the 
epitope would include residue 275. Docking simulations of these model 
epitopes were then performed with the CDR of 6E3 using the AutoDock 
program to calculate the binding free energies and the optimal binding 
modes (Morris et al., 1998). Of the 20 binding conformations of the 
model epitopes generated with the genetic algorithm, those differing by 
< 1.5 Å in the positional root-mean-square deviation were clustered 
together. The epitope conformations with the lowest docking free en-
ergy in the top-ranked cluster were adopted as the final binding modes 
for the 6E3 antibody. 
2.5. H275Y pH1N1 detection 
For dot-blot analysis, the NC membrane was spotted with WT pH1N1 
and H275Y pH1N1 in a two-fold dilution series from 0.92 to 7.4 × 106 
PFU/mL. The virus-spotted membrane was incubated with 1 μg/mL of 
6E3 in PBS containing 0.1% BSA and 0.05% Tween 20 for 1 h at 25 ◦C, 
and then washed three times with PBS containing 0.05% Tween 20. 
HRP-conjugated goat anti-human IgG was used for the detection of 
bound IgG. The membrane was covered with the SuperSignal West 
Femto reagent (Thermo), and chemiluminescence detection was per-
formed with the ChemiDoc system (Bio-Rad, CA, USA). 
For colorimetric detection, 10 μg 6E3 antibody was added to a 
mixture of 1 mL Au NPs (20 nm) and 0.1 mL borate buffer (0.1 M, pH 
8.5). After incubation for 30 min at 25 ◦C, 0.1 mL 1% BSA was added to 
block the surface of the Au NPs. After incubation for 1 h at 4 ◦C, the 6E3- 
Au NPs were collected by centrifugation at 16,000×g for 15 min at 4 ◦C 
and resuspended in deionized water. For the detection of the H275Y 
pH1N1 virus, a 100 μL virus sample (105 PFU/mL) was mixed with 50 μL 
6E3-Au NPs and incubated for 30 min. The blank, WT pH1N1 (105 PFU/ 
mL), and RSV (105 PFU/mL) samples were tested following the same 
procedure. The absorbance of 6E3-Au NPs was measured using a mul-
tidetection microplate reader (Cytation 5, BioTek, VT, USA). 
The LFA test strip was prepared as follows. The sample pad was 
saturated with PBS solution containing 0.2% Tween 20 and 1% BSA. 
After drying the sample pad at 25 ◦C, it was stored in a desiccator for 
future use. The anti-influenza A nucleoprotein IgG-Au NPs were pre-
pared following the procedure for the 6E3-Au NPs but employing the IgG 
instead of 6E3. The prepared Au NP probes were added to the conju-
gation pad, dried at 25 ◦C for 2 h, and stored in a desiccator. The 6E3 
antibody and goat anti-human IgG (1 mg/mL) were immobilized on the 
NC membrane as the test and control lines, respectively. After the NC 
membrane was dried, the membrane was blocked with 1% BSA. All 
components were assembled on the backing card, and the final LFA test 
strip was transferred to a strip cassette. For the assay, 150 μL of the 
sample was directly applied to the sample pad and spread across the 
strip within 5 min. 
For the RT-PCR assay, the following primers were used according to 
previous literature (E. van der Vries et al., 2013); H275Y F: 5′
AAAAGGGGAAGGTTACTAAATCAATAGAGT, H275Y R: 5′
CAGTGTCTGGGTAACAGGAGCATT. A total of nine sets were tested, one 
set consisted of no template control (NTC), bare, WT pH1N1-spiked, and 
H275Y mutant pH1N1-spiked human nasopharyngeal aspirate samples. 
Viral RNA of each sample was extracted by using QIA amp viral RNA 
mini kit (Qiagen, VT, Australia) following standard protocol. Each 
RT-PCR reaction mixture contained 10 μL of AccuPower greenstar 
RT-qPCR 2 × master mix (Bioneer, Daejeon, Korea), 10 pmole of each 
primer, and 10 ng of RNA template in a final volume of 20 μL. Each 
reaction was performed using the following amplification conditions: 
reverse transcription reaction to get cDNA at 60 ◦C for 15 min, and PCR 
amplification at 95 ◦C for 3 min, followed by 40 cycles at 95 ◦C for 30 s 
and 62 ◦C for 30 s. Amplification and detection was performed on a 
CFX96 Touch RT-PCR detection system (Biorad, CA, USA) using the 
carboxy-X-rhodamine (ROX) filter (578–604 nm). 
2.6. 6E3 antibody-mediated SERS immunoassay 
For the preparation of the Au nanoplate immune substrate, Au 
nanoplates were synthesized in a vapor-phase as previously described 
(Yoo et al., 2017). As-synthesized Au nanoplates were incubated with 
Cys3-protein G solution in PBS (10 nM) for 18 h at 4 ◦C and rinsed with 
PBS three times. The protein G-modified Au nanoplates were incubated 
with 6E3 antibody in PBS (100 ng/mL) for 18 h at 4 ◦C and rinsed with 
PBS three times. For preparing the Au NP immunoprobes, 100 μL MGITC 
in ethanol (10 μM) was added to the Au NP solution to a final volume of 
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1 mL, and the Au NP solution was incubated for 45 min at 25 ◦C under 
orbital shaking. Next, the solution was centrifuged (13,500×g) for 15 
min and resuspended in PBS. Next, 10 μL HS–(CH2)10–NHS in tetrahy-
drofuran (10 μM) and 100 μL 6E3 antibody in PBS (100 ng/mL), were 
mixed and the solution was stored for 45 min at 4 ◦C under orbital 
shaking. The mixed solution (50 μL) was added to the prepared Au NP 
solution, and this solution was incubated for 45 min at 25 ◦C under 
orbital shaking. Thereafter, 1.15 μL Tris-HCl buffer (1 M, pH 6.8) was 
added to the Au NP solution for 30 min at 25 ◦C under orbital shaking. 
Lastly, the Au NP solution was centrifuged (13,500×g) for 15 min and 
resuspended in PBS. 
For the detection of viruses, various concentrations of the H275Y and 
WT viruses were diluted in PBS. The virus samples were incubated with 
immune substrates for 1 h at 4 ◦C under shaking. Then, the immune 
substrates were rinsed with PBS three times and incubated in the Au NP 
immunoprobe solution for 45 min at 25 ◦C. SERS spectra were measured 
after washing with distilled water and drying with N2 gas. A micro- 
Raman system based on an Olympus BX41 microscope (Nanobase, 
Seongnam, Korea) was used for the SERS measurements. The excitation 
source was a He–Ne laser operating at λ = 633 nm (20 μW). The laser 
spot was focused on a sample through a 50 × objective lens. The SERS 
signals were recorded with a thermodynamically cooled electron- 
multiplying charge-coupled device mounted on a spectrometer with a 
1200-groove/mm grating. SEM images were obtained on a Nova 230 
system at an accelerating voltage of 15 keV (FEI, OR, USA). 
Nasopharyngeal aspirate samples from patients were collected with 
the flocked nasopharyngeal swabs and transferred to the virus transport 
media (UTM, Copan Diagnostics Inc., CA, USA). All samples were stored 
at − 70 ◦C before use. The protocol for this retrospective study was 
reviewed and approved by the Institutional Review Board of Yonsei 
University Health Service, Severance Hospital, Seoul, Korea (IRB 
approval number: 4-2017-1179). For the detection of viruses in human 
nasopharyngeal aspirate samples, the collected samples were thawed at 
25 ◦C, and 10 μL influenza viruses (103 PFU/mL; WT or H275Y pH1N1) 
were spiked into each specimen (90 μL). The virus-spiked samples were 
diluted 10-fold with PBS and were used as the samples for diagnosis. 
3. Results 
3.1. Production of 6E3 antibody 
For the development of a monoclonal antibody against the 
oseltamivir-resistant influenza virus, we employed a large human 
antigen-binding fragment (Fab) phage display library and a biopanning 
protocol including a subtraction step against WT NA. Fig. 1A shows the 
ELISA results for monoclonal phages after different rounds of panning. 
Upon further rounds of panning, WT NA binders were removed (red 
column in Fig. 1A), and H275Y NA-specific phages remained (blue 
column in Fig. 1A). After three rounds of biopanning, the clone that 
strongly bound the H275Y NA (6E3) was subjected to DNA sequencing, 
obtaining the unique clone shown in Fig. 1B. Finally, we converted the 
Fab form of 6E3 to the whole immunoglobulin G (IgG) form (6E3 anti-
body) for use in the diagnosis of H275Y-bearing antiviral drug-resistant 
influenza virus (Fig. 1C). 
3.2. Binding of 6E3 antibody to H275Y NA 
After the production of the 6E3 antibody, the binding affinities of the 
6E3 antibody to WT and H275Y NA were measured by ELISA (Fig. 2A). 
The 6E3 antibody strongly bound to H275Y NA with a dissociation 
constant (KD) of 32.76 pM. In contrast, the KD of the 6E3 antibody to WT 
NA was 72.74 μM. The cross-reactivity of the 6E3 antibody was also 
examined by ELISA (Fig. 2B). The absorbance values increased only in 
the presence of H275Y NA. The absorbance values of bovine serum al-
bumin (BSA), DENV1-EP, HG-NS1-3-6H, CHIKV-EP2, and JEV-E domain 
III were comparable to that of WT NA. These results indicate that the 
selected 6E3 antibody can specifically recognize the H275Y NA. 
In Fig. 2C and D, the calculated binding modes of the 6E3 model 
epitopes in the WT and H275Y mutant NAs are displayed. The two 
epitopes appear to reveal a similar complexation pattern in the 
complementarity determining region (CDR) of 6E3. Most remarkably, 
the aromatic side chain of 275 residue points toward a small hydro-
phobic pocket comprising the three tryptophan residues of 6E3 (Trp 33 
Fig. 1. (A) Screening for the H275Y NA specificity of the monoclonal phages from three rounds of panning by ELISA with HRP-conjugated αM13. Error bars =
standard deviation (n = 3). (B) Amino acid sequence of 6E3. (C) SDS-PAGE analysis of purified 6E3 under reducing (R) and non-reducing (NR) conditions. Lane M: 
protein marker; HC: heavy chain; LC: light chain. 
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Fig. 2. (A) Plot of absorbance at 450 nm as a function of WT (black) and H275Y (blue) NA concentration. Error bars = standard deviation (n = 3). (B) Plot of 
absorbance at 450 nm versus proteins. Absorbance at 450 nm increased only in the presence of H275Y NA. Error bars = standard deviation (n = 3). (C, D) Docking 
conformation and calculated binding free energies of the model epitopes for (C) WT and (D) H275Y NAs in the CDR of 6E3 antibody. (For interpretation of the 
references to color in this figure legend, the reader is referred to the Web version of this article.) 
Fig. 3. (A) Specific interaction between the 6E3 antibody and H275Y pH1N1 virus by dot-blot analysis. The 6E3 antibody was applied to WT and H275Y pH1N1 
viruses dotted in a two-fold dilution series from 0.92 to 7.4 × 106 PFU/mL. (B) The plot of absorbance at 450 nm versus viruses tested. Absorbance increased in the 
presence of H275Y or I223 R/H275Y mutant viruses. Error bars = standard deviation (n = 3). (C) Absorbance spectra (left) and photograph (right) of 6E3-Au NPs in 
the presence of blank, WT, and H275Y pH1N1 viruses and RSV samples. The concentration of each virus was 105 PFU/mL. (D) Photograph of lateral flow systems 
after the detection of H275Y pH1N1 virus (0.02–7.4 × 106 PFU/mL), WT pH1N1 virus (7.4 × 106 PFU/mL), and blank samples. 
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and Trp 50 in the light chain, and Trp 103 in the heavy chain). The 
phenol side chain of Tyr275 in the mutant NA is closer than the imid-
azole group of His 275 in the WT NA to the tryptophan triad in 6E3. The 
van der Waals volume increases due to the substitution of tyrosine for 
histidine. As a consequence, the AutoDock binding free energy for the 
6E3 antibody decreases from − 16.1 to − 18.7 kcal/mol as the epitope 
changes from the WT to H275Y mutant, which is consistent with the 
higher binding affinity to the latter. We further performed docking 
simulations using the extended 3-dimensional (3D) grid maps including 
the entire antibody structure, to check for the presence of the other 
stable binding configurations. No peripheral binding pocket in which an 
epitope could be complexed with the negative value of binding free 
energy was found. This supports the reliability of the docking poses 
derived from AutoDock. 
3.3. Application of 6E3 antibody to H275Y pH1N1 detection 
6E3 antibody was employed for the detection of oseltamivir-resistant 
pH1N1 by combining several techniques. First, dot-blot tests were 
accomplished using WT and H275Y mutant pH1N1 virus-spotted 
nitrocellulose (NC) membranes (Fig. 3A). On the mutant pH1N1- 
spotted membrane, distinct spots were observed in a virus- 
concentration dependent manner. On the WT virus-spotted membrane, 
no spots were observed. The dot-blot tests clearly show that the 6E3 
antibody can detect the H275Y mutant influenza virus. 
Second, ELISA tests were performed using WT, H275Y, I223R, 
I223R/H275Y mutant viruses and human respiratory syncytial virus A2 
(RSV). Absorbance significantly increased in the presence of the H275Y 
mutant virus (Fig. 3B). In the presence of WT, I223R pH1N1, and RSV, 
weak signals were obtained (Fig. 3B). Interestingly, the 6E3 antibody 
could recognize the double-mutant virus (I223 R/H275Y pH1N1) 
(purple bar in Fig. 3B). Previous study revealed that the H275Y substi-
tution has a major effect on the binding pose within the active site while 
the influence of other mutations is much less prominent (Pokorná et al., 
2018). This might attribute that the 6E3 antibody recognizes not only 
the H275Y mutation but also I223 R/H275Y double mutations. 
Third, the 6E3 antibody was combined with Au NPs for colorimetric 
detection of the H275Y mutant virus. The bare 6E3-Au NPs exhibit 
reddish color with maximum absorption at 534 nm (black spectrum in 
Fig. 3C). When the 6E3-Au NPs were mixed with WT pH1N1 or RSV, the 
color and absorbance of the NPs were preserved (Fig. 3C). When the 
6E3-NPs were mixed with the oseltamivir-resistant virus, the absorbance 
peak was red-shifted and broadened (Fig. 3C). The color of 6E3-NPs also 
changed to purple after mixing with H275Y pH1N1. This change is 
attributed to the binding of the 6E3-NP to the H275Y NA of mutant 
viruses. 
Lastly, LFA for the H275Y pH1N1 virus was developed using the 6E3 
antibody. Briefly, the anti-influenza A nucleoprotein IgG-Au NPs were 
added to the conjugation pad as a detection probe. The 6E3 antibody and 
the goat anti-human IgG were lined on the NC membrane as the test and 
control lines, respectively. This LFA test strip is expected to display two 
red lines (test and control lines) when the H275Y mutant pH1N1 virus is 
present in a sample. As shown in Fig. 3D, the test lines showed reddish 
colors after the addition of the H275Y mutant viruses to the membranes. 
The color of the test line became more distinct with increasing con-
centrations of the mutant virus. By using the developed LFA test strip, 
the H275Y pH1N1 virus could be detected at a low concentration of 2 ×
105 plaque-forming units (PFU)/mL. At a lower concentration, the red 
line was indistinguishable. The LFA did not react with the WT pH1N1 
(7.4 × 106 PFU/mL). The blank sample also showed no signal. 
3.4. 6E3 antibody-mediated SERS immunoassay for H275Y pH1N1 
Although the 6E3 antibody was applied to several kinds of ap-
proaches for the detection of the H275Y mutant virus, the detection 
limits were still high and needed improvement. Therefore, we tried to 
combine the 6E3 antibody with the SERS-based immunoassay using 
atomically flat Au nanoplates. The well-immobilized bioreceptors on flat 
and clean surfaces are promising immune substrates in the development 
of high-performance immunological sensors as they can provide repro-
ducible SERS signals and prevent nonspecific binding (Hwang et al., 
2019). Previous reports support that the atomically flat Au nanoplate 
platforms enable the sensitive and selective detection of biomolecules 
(Eom et al., 2019a,b; Hwang et al., 2019; Lee et al., 2018). The sche-
matic illustration of the H275Y mutant virus detection by 6E3 
antibody-mediated SERS immunoassay is shown in Fig. 4A. For the 
preparation of the immune substrate, the 6E3 antibody was immobilized 
on a single-crystalline Au nanoplate. In brief, the vapor-phase grown Au 
nanoplates were incubated with three cysteine-tagged protein G 
(Cys3-protein G) and washed. Protein G binds the crystallizable frag-
ment (Fc) of an antibody, thereby enabling effective exposure of the 
antibody to its antigen (Hwang et al., 2019). Next, the 6E3 antibody was 
immobilized on the protein G-coated Au nanoplate and washed. For the 
preparation of the immunoprobes, the surfaces of Au NPs were simul-
taneously modified with 6E3 antibody and MGITC, a well-known Raman 
reporter (Sharma et al., 2012). In this experiment, we immobilized the 
6E3 antibody on both Au nanoplates and NPs to increase the specificity 
of the H275Y pH1N1 virus detection. In general sandwich immunoas-
says, two different types of antibodies are employed (Deiss et al., 2009; 
Rissin and Walt, 2006; Sánchez-Purrà et al., 2017). The current 
SERS-based immunoassay, however, employed a single 6E3 antibody 
because a single pH1N1 virus particle has over 200 NA proteins (Eom 
et al., 2019a,b), allowing a sufficient 6E3-H275Y-6E3 sandwich forma-
tion. For the detection of the drug-resistant virus using the 6E3-mediated 
SERS immunoassay, the 6E3-Au nanoplates were allowed to react with 
virus samples (WT or H275Y pH1N1), and the immunoprobes were 
incubated. In the presence of the H275Y mutant virus, the Au 
NP-on-nanoplate structure can be formed. This nanostructure can pro-
vide strong SERS signals of MGITC near the gaps between the NPs and 
the nanoplate. In contrast, in the presence of only the WT pH1N1 virus, 
the Au NPs do not assemble on the nanoplate, yielding negligible SERS 
signals. 
We then examined the results of H275Y pH1N1 virus detection using 
the 6E3 antibody-mediated SERS immunoassay. As shown in Fig. 4B, the 
control sample showed no SERS signal. Meanwhile, the SERS signals of 
MGITC increased with increasing mutant virus concentrations. The 
scanning electron microscope (SEM) images of Au NPs-on-nanoplate 
structures from which we obtained the SERS signals are shown in 
Fig. S1 of Supporting Information. The SERS signals for 102 PFU/mL of 
the mutant pH1N1 are distinguishable from those of the control sample, 
indicating that the detection limit of the 6E3 antibody-mediated SERS 
immunoassay is 102 PFU/mL. Fig. 4C is the plot of integrated 1615 cm− 1 
band intensity as functions of WT and H275Y pH1N1 virus concentra-
tions. This further suggests that the 6E3 antibody-mediated SERS 
immunoassay can detect the mutant virus quantitatively. In addition, we 
investigated the selective detection of the H275Y mutant virus in a 
mixture of WT and mutant viruses using the SERS-based method. In the 
mixture samples, the number of H275Y pH1N1 mutant viruses was 
varied at 0, 102, 103, 104 and 105 PFU/mL and the number of WT pH1N1 
viruses was fixed at 105 PFU/mL. As shown in Fig. S2, the SERS signals 
of MGITC gradually increased as the concentration of H275Y mutant 
virus increased. The 6E3 antibody-mediated SERS immunoassay could 
detect 0.1% H275Y mutant virus in the mutant (102 PFU/mL) and WT 
(105 PFU/mL) virus-coexisting mixture. Notably, the SERS signals for 
WT pH1N1 detection are negligible regardless of virus concentration. 
Thus, the 6E3 antibody and Au nanoplate platform synergistically 
contributed to the sensitive and selective detection of the oseltamivir- 
resistant influenza virus. 
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3.5. Direct detection of H275Y pH1N1 in human nasopharyngeal 
aspirate 
The human nasopharyngeal aspirate samples are most frequently 
used for the diagnosis of respiratory virus infection in patients (Paton 
et al., 1992; Peiris et al., 2003). Therefore, we tried to detect the 
oseltamivir-resistant virus in the human nasopharyngeal aspirate using 
the 6E3 antibody-mediated SERS immunoassay. The nasopharyngeal 
samples were provided from a tertiary hospital in Korea after approval. 
These samples were collected from the patients with flu symptoms but 
who were negatively diagnosed for flu. As the presence of antiviral 
drug-resistant viruses is currently not tested in the hospital, the H275Y 
mutant virus was intentionally added into the collected nasopharyngeal 
swab samples and examined by the 6E3 antibody-mediated SERS 
immunoassay (Fig. 5A). A total of nine H275Y pH1N1-spiked human 
nasopharyngeal aspirate samples was examined, and the final concen-
tration of the H275Y virus was 103 PFU/mL. Fig. 5B shows the SERS 
spectra of MGITC after the detection of the H275Y mutant virus in 
human nasopharyngeal aspirate samples using the 6E3-mediated SERS 
immunoassay. All nine samples provided positive SERS signals, indi-
cating the successful detection of the mutant viruses. Note that the 
H275Y pH1N1-spiked nasopharyngeal swab samples were directly 
employed without pre-treatment steps. This suggests that the assay is 
useful for the diagnosis of drug-resistant pH1N1 virus-infected patients. 
We further investigated the 6E3-mediated SERS immunoassay by 
comparing the diagnostic results of H275Y pH1N1- and WT 
pH1N1-spiked nasopharyngeal aspirate and control samples. Blue bars 
in Fig. 5C represent the integrated 1615 cm− 1 band intensities obtained 
from the mutant virus-spiked human nasopharyngeal aspirates samples, 
corresponding to the result of Fig. 5B. Red bars are the integrated band 
intensities from the WT pH1N1-spiked samples. Black bars are the in-
tegrated band intensities from the bare nasal samples. The full SERS 
spectra of Fig. 5C are shown in Fig. S2 of Supporting Information. Strong 
SERS signals were observed only in the presence of H275Y pH1N1, 
indicating that 6E3 antibody-mediated SERS immunoassay can recog-
nize the mutant virus in human nasopharyngeal aspirate samples. The 
fluctuating SERS signals in the control and WT pH1N1-spiked naso-
pharyngeal aspirate samples may be attributed to nonspecific binding 
with biological species in the nasopharyngeal aspirate samples. Never-
theless, all H275Y-spiked nasopharyngeal aspirate samples provided 
positive SERS signals, proving accurate diagnosis of the 
oseltamivir-resistant pH1N1. The PCR result also agrees well with the 
SERS result (Fig. S4). 
4. Discussion 
Influenza viruses cause seasonal epidemics almost every winter. 
Patients with flu symptoms such as coughs, sore throat, fever, etc., are 
diagnosed in hospitals through RIDTs. When the test result is positive for 
influenza viruses, a doctor may prescribe an antiviral medication such as 
oseltamivir, zanamivir, etc. Unfortunately, drug-resistant influenza vi-
ruses are becoming increasingly dominant; a previous report suggested 
that 27% of A H1N1 virus-infected children exhibited resistance after 
treatment with oseltamivir (Stephenson et al., 2009). Thus, the growing 
number of drug-resistant pH1N1 viruses is a cause of concern for the 
treatment of flu patients. To address this issue, the Centers for Disease 
Fig. 4. (A) Schematic illustration of 6E3 antibody-mediated SERS immunoassay for WT and H275Y pH1N1 viruses. (B) SERS spectra of MGITC as a function of 
H275Y pH1N1 concentration (0, 102, 103, 104, and 105 PFU/mL). (C) Plot of integrated 1615 cm− 1 band intensity versus WT pH1N1 and H275Y pH1N1 virus 
concentrations. Error bars = standard deviation (n = 10). 
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Control and Prevention of the United States (CDC) conducts ongoing 
surveillance and testing for seasonal and novel influenza viruses with 
reduced susceptibility and acquired resistance to antivirals (Oko-
mo-Adhiambo et al., 2014). NA inhibitors (NAIs), that selectively target 
the NA of pH1N1, play a key role in the management of influenza 
infection (Hussain et al., 2017; Lackenby et al., 2018; Ishiguro et al., 
2018). Because NAIs remain the only widely licensed class of antiviral 
drugs appropriate for the treatment and prophylaxis of seasonal flu 
(Ishiguro et al., 2018; Earn et al., 2002). Given the very limited number 
of anti-influenza therapeutic agents, preparedness for a potential future 
influenza pandemic has focused on the emergence of NAI-resistant virus 
mutations (Ishiguro et al., 2018; Earn et al., 2002; Baranovich et al., 
2010). Among the limited NAIs, oseltamivir has been most extensively 
prescribed (Ishiguro et al., 2018; Laplante et al., 2014). Therefore, the 
NA mutations exhibiting the oseltamivir resistance have been most 
frequently reported (Laplante et al., 2014). Considering that numerous 
research results of drug resistance are related to H275Y mutation 
(Laplante et al., 2014; Kelso and Hurt, 2012; Pizzorno et al., 2011), it is 
urgently required to develop the identification methods for H275Y NA 
mutation. 
Previously, we developed oseltamivir hexylthiol (OHT) as a chemical 
receptor for the H275Y pH1N1 virus (Eom et al., 2019a,b; Hwang et al., 
2018). The A4 antibody against the double-mutant influenza viruses was 
also developed by our group (Guk et al., 2020). In this study, we report a 
6E3 antibody against the H275Y mutant pH1N1 influenza virus. The 
strong binding affinity of the 6E3 antibody to H275Y NA enables the 
recognition of the oseltamivir-resistant pH1N1 virus. Compared with a 
chemical receptor, an antibody could be used for a wider range of im-
munoassays. Moreover, the 6E3 antibody could have a higher value than 
the A4 antibody in clinical diagnostic uses as the 6E3 antibody recog-
nizes not only H275Y mutation but also I223 R/H275Y double muta-
tions. In fact, the H275Y mutation occurs much more frequently than the 
I223 R/H275Y double mutations (Paradis et al., 2015). Furthermore, we 
developed an advanced immunological approach for detecting 
drug-resistant viruses in human nasopharyngeal aspirate samples by 
combining the 6E3 antibody with nanomaterials. The previous SERS 
approach using the A4 antibody simply demonstrated the detection of 
the double mutant virus in the buffer (Guk et al., 2020). More impor-
tantly, we shortened the detection time of SERS immunoassay from 7 to 
2 h in this study. Recently, immunoassays have been combined with 
various nanotechnologies for developing sophisticated and sensitive 
sensing methods (Lee et al., 2018). The SERS immunoassay developed in 
this study for detecting drug-resistant pH1N1 influenza viruses may 
contribute to the prevention of severe diseases by ensuring appropriate 
treatments. As two kinds of biological (6E3 antibody) and chemical 
(OHT) receptors are available for the detection of the 
oseltamivir-resistant virus, in the future, we will try to fuse these two 
molecules and apply them to high-quality nanomaterials to further in-
crease the precision of diagnosis of the drug-resistant pH1N1 influenza 
virus. 
5. Conclusion 
In this study, we developed the 6E3 antibody against the H275Y 
mutant pH1N1 influenza virus with a KD of 32.76 pM for H275Y NA. The 
6E3 antibody was applied to dot-blot, ELISA, colorimetry, and LFA, 
showing wide applicability. We also immobilized the 6E3 antibody to an 
Au nanoplate and NPs to demonstrate SERS-based detection of the 
H275Y mutant pH1N1 virus. The 6E3-mediated SERS immunoassay 
allowed the detection of the drug-resistant virus at a low concentration 
of 102 PFU/mL. We also verified that the developed assay could be 
useful for the diagnosis of H275Y pH1N1 in human nasopharyngeal 
aspirate samples. The present results provide a new method for diag-
nosing antiviral drug-resistant influenza viruses and further contribute 
to the prevention of the re-emergence of infectious diseases. 
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Sánchez-Purrà, M., Carré-Camps, M., de Puig, H., Bosch, I., Gehrke, L., Hamad- 
Schifferli, K., 2017. ACS infect. Dis 3, 767–776. 
Sharma, B., Frontiera, R.R., Henry, A.-I., Ringe, E., Van Duyne, R.P., 2012. Mater. Today 
Off. 15, 16–25. 
Sharma, A., Tiwari, S., Deb, M.K., Marty, J.L., 2020. Antimicrob. Age 56, 106054. 
Shetty, A.K., Peek, L.A., 2012. Expert rev. Anti-Infect. Ther 10, 123–143. 
Stephenson, I., Democratis, J., Lackenby, A., McNally, T., Smith, J., Pareek, M., Ellis, J., 
Bermingham, A., Nicholson, K., Zambon, M., 2009. Clin. Infect. Dis. 48, 389–396. 
Taubenberger, J.K., Kash, J.C., Morens, D.M., 2019. Sci. Transl. Med. 11, eaau5485. 
Tolentino-Lopez, L., Segura-Cabrera, A., Reyes-Loyola, P., Zimic, M., Quiliano, M., 
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